1. Introduction {#sec1-marinedrugs-18-00303}
===============

The so called marine-derived fungi have been isolated from a wide array of marine organisms such as mangroves, algae, sponges and corals, whose habitats distribute from deep sea to intertidal zone. Among these, algae-derived fungi have been reported to be the largest source of secondary metabolites with diversified bioactivities \[[@B1-marinedrugs-18-00303],[@B2-marinedrugs-18-00303]\], and that can be exploited potentially as lead compounds for new drug development. It was reported that by employing one of the post-genomic strategies, one strain many compounds (OSMAC), on the cultivation of the fungal strains could enhance the quantity and diversity of fungal secondary metabolites \[[@B3-marinedrugs-18-00303],[@B4-marinedrugs-18-00303]\]. The OSMAC approach usually involved the manipulation of culturing parameters, such as media formulation, temperature, agitation, luminosity, aeration, etc. \[[@B5-marinedrugs-18-00303],[@B6-marinedrugs-18-00303],[@B7-marinedrugs-18-00303]\]. In addition. easy to scale-up and quality control of the fungal metabolites would be another major advantage that made fungi to be one of the best options for natural product research and new lead discovery.

Taiwan is an island located at tropical and subtropical region with highly diversified marine algal species \[[@B8-marinedrugs-18-00303]\], indicating an abundant resource of the fungal endophytes. However, the chemical investigation on the local algae-derived fungal strains are still rare so far. Thus, an efficient agar-based disc diffusion assay was applied for the preliminary biological screening against *Escherichia coli*, *Staphylococcus aureus*, *Candida albicans* and *Cryptococcus neoformans* \[[@B9-marinedrugs-18-00303]\], the ethyl acetate extracts of fermented broths of *Aspergillus giganteus* NTU967 derived from the green alga *Ulva lactuca* were found to exhibit significant inhibition zone against *S. aureus* and *C. neoformans*. Therefore, chemical investigation on both the fermented products of *Aspergillus giganteus* NTU967 was performed, and this has resulted in the isolation and identification of seven previously unreported highly oxygenated polyketides **1**--**7** ([Figure 1](#marinedrugs-18-00303-f001){ref-type="fig"}) together with four known compounds. This study describes the isolation and characterization of the new compounds together with their bioactivities (see [Supplementary Materials](#app1-marinedrugs-18-00303){ref-type="app"}).

2. Results and Discussion {#sec2-marinedrugs-18-00303}
=========================

2.1. Isolation and Characterization of Secondary Metabolites {#sec2dot1-marinedrugs-18-00303}
------------------------------------------------------------

In this study, the green alga *Ulva lactuca*-derived fungal strain *Aspergillus giganteus* NTU967 was cultured in both solid- and liquid--state culturing conditions in order to enrich the diversity of the fungal secondary metabolites and eleven chemical entities including seven new compounds **1**--**7** and four previously reported compounds, patulin, deoxytryptoquivaline, tryptoquivaline and quinadoline B, were obtained from the fermented products. Of the known compounds isolated, patulin, a highly oxygenated C~7~ mycotoxin, with a hemiacetal functionality is apt to racemize naturally to form a pair of enantiomers and was first characterized in 1943 under the name of tercinin as a potential antimicrobial agent \[[@B10-marinedrugs-18-00303]\]. Recently, patulin in combination with oxaliplatin were found to exhibit synergism against human colorectal cancer \[[@B11-marinedrugs-18-00303]\]. Deoxytryptoquivaline, tryptoquivaline and quinadoline---three quinazolone-containing alkaloids---were identified by comparison of spectroscopic data with literatures \[[@B12-marinedrugs-18-00303],[@B13-marinedrugs-18-00303]\]. In addition to be isolated from *Aspergillus* spp., a series of tryptoquivaline analogs have ever been obtained from a marine sea fan-derived fungus *Neosartorya siamensis* \[[@B14-marinedrugs-18-00303]\].

Compound **1**, obtained as colorless oil, was determined to have a molecular formula of C~9~H~12~O~5~, as evidenced by its ^13^C NMR spectrum ([Table 1](#marinedrugs-18-00303-t001){ref-type="table"}) and a pseudomolecular ion \[M + Na\]^+^ at *m*/*z* 223.0574 (calcd. 223.0582 for C~9~H~12~O~5~Na) in the positive mode of HRESIMS analysis. The IR absorptions at 1745 and 1672 revealed the presence of an ester carbonyl and a conjugated ketone functionality, respectively. The ^1^H NMR (CD~3~OD, 400 MHz) of compound **1** revealed two oxygen-bearing three-proton signals at δ~H~ 3.35 (H~3~-8) and 3.71 (H~3~-9), one methylene signal at δ~H~ 2.61 (d, *J* = 6.2 Hz, H~2~-2), one oxygen-bearing methylene signal at δ~H~ 4.55 (H~2~-7), one oxygen-bearing methine signal at δ~H~ 4.55 (H-3) and an olefinic methine signal at δ~H~ 7.66 (s, H-6) ([Table 2](#marinedrugs-18-00303-t002){ref-type="table"}). The ^13^C NMR (CD~3~OD, 125 MHz) coupled with phase-sensitive HSQC spectrum of compound **1** showed nine signals including two methoxyl carbons at δ~C~ 57.7 (C-8) and 52.7 (C-9), one methylene carbon at δ~C~ 36.7 (C-2), one oxymethylene carbon at δ~C~ 75.9 (C-7), one oxygenated methine carbon at δ~C~ 69.7 (C-3), one oxygenated olefinic carbon at δ~C~ 166.1 (C-6), one nonprotonated olefinic carbon at δ~C~ 116.2 (C-5), one ester carbonyl carbon at δ~C~ 172.9 (C-1) and one conjugated ketone carbon at δ~C~ 191.8 (C-4) ([Table 1](#marinedrugs-18-00303-t001){ref-type="table"}). On account of the molecular formula C~9~H~12~O~5~, the double bond equivalent (DBE) of compound **1** was four including a double bond and two carbonyl groups. Thus, there should be one additional ring in compound **1**. Further two dimensional NMR analysis including one cross-peak of δ~H~ 2.61 (H~2~-2)/δ~H~ 4.55 (H-3) in the COSY spectrum of compound **1** in combination with key correlations of δ~H~ 2.61 (H~2~-2)/δ~C~ 69.7 (C-3) and 191.8 (C-4); δ~H~ 4.55 (H-3)/δ~C~ 172.9 (C-1) and 191.8 (C-4); δ~H~ 7.66 (H-6)/δ~C~ 69.7 (C-3), 191.8 (C-4), 116.2 (C-5) and 75.9 (C-7); δ~H~ 4.55 (H~2~-7)/δ~C~ 191.8 (C-4); δ~H~ 3.35 (H~3~-8)/δ~C~ 75.9 (C-7); δ~H~ 3.71 (H~3~-9)/δ~C~ 172.9 (C-1) in the HMBC spectrum of compound **1** ([Figure 2](#marinedrugs-18-00303-f002){ref-type="fig"}), corroborated the gross structure of **1**. The optical rotation value of compound **1** (\[α\] ^27^~D~ −0.36) was close to zero, revealing that compound **1** could be a racemate.

The molecular formula of **2**, C~9~H~12~O~5~, was deduced through analysis of its ^13^C NMR and HRESIMS data. Its IR spectrum revealed the presence of an ester carbonyl (1737 cm^−1^) and a conjugated ketone group (1673 cm^−1^). The ^1^H NMR spectrum of compound **2** coupled with phase-sensitive HSQC spectrum showed two methoxyl signals at δ~H~ 3.45 (s, H~3~-8) and 3.67 (s, H~3~-9), one methylene signal at δ~H~ 3.14 (s, H~2~-2), one oxygenated methylene signal at δ~H~ 4.49 (d, *J* = 4.7 Hz, H~2~-6), one carbinoyl methine signal at δ~H~ 3.70 (t, *J* = 4.7 Hz, H-5), and one olefinic methine signal at δ~H~ 7.50 (s, H-7) ([Table 2](#marinedrugs-18-00303-t002){ref-type="table"}). Nine carbon resonances including two methoxyl at δ~C~ 58.7 (C-8) and 52.5 (C-9), one oxygenated methylene at δ~C~ 72.3 (C-6), one methylene at δ~C~ 31.1 (C-2), one olefinic methine at δ~C~ 164.0 (C-7), one carbinoyl methine at δ~C~ 77.3 (C-5), one nonprotonated olefinic carbon at δ~C~ 111.7 (C-3), one ester carbonyl carbon at δ~C~ 173.6 (C-1), and one ketone carbon at δ~C~ 191.3 were observed in the ^13^C NMR of compound **2** ([Table 1](#marinedrugs-18-00303-t001){ref-type="table"}), which were supported by phase-sensitive HSQC spectrum. On account of the molecular formula of **2**, C~9~H~12~O~5~, compound **2** would contain a ring in addition to a double bond, a ketone and an ester carbonyl to fit the unsaturation number. Further comprehensive analysis of two dimensional NMR spectra of compound **2** ([Figure 2](#marinedrugs-18-00303-f002){ref-type="fig"}), one cross-peak of δ~H~ 3.70 (H-5)/δ~H~ 4.49 (H~2~-6) in the COSY spectrum together with key cross-peaks of δ~H~ 3.14 (H~2~-2)/δ~C~ 111.7 (C-3); δ~H~ 4.49 (H~2~-6)/δ~C~ 191.3 (C-4); δ~H~ 7.50 (H-7)/δ~C~ 31.3 (C-2), 111.7 (C-3), 191.3 (C-4) and 72.3 (C-6); δ~H~ 3.45 (H~3~-8)/δ~C~ 77.3 (C-5); δ~H~ 3.67 (H~3~-9)/δ~C~ 173.6 (C-1) in the HMBC spectrum established the structure of **2**.

The physical and NMR data of compound **3** and compound **4** were almost compatible with those of patulin except that an additional methyl and an additional ethyl were observed in the ^1^H and ^13^C NMR spectra of compound **3** and compound **4** ([Table 1](#marinedrugs-18-00303-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00303-t002){ref-type="table"}), respectively. The pseudomolecular ion \[M + H\]^+^ at *m*/*z* 169.0493 and 183.0655 in the HRESIMS of compounds **3** and **4**, 14 and 28 Da more than that of patulin, confirmed that compound **3** and compound **4** were the methyl and ethyl derivatives of patulin, respectively. In the HMBC spectra of compounds **3** and **4**, distinctive cross-peaks of δ~H~ 3.54 (H~3~-8)/δ~C~ 95.9 (C-7) and δ~H~ 3.71 and 3.91 (H~2~-8)/δ~C~ 94.8 (C-7) indicated the methyl and ethyl groups were attached to C-7 of compounds **3** and **4**, respectively. The structures of compound **3** and compound **4** were thus elucidated to be as shown.

Compound **5**, obtained as colorless oil, was determined to have a molecular formula of C~10~H~14~O~5~, as evidenced by its HRESIMS analysis and ^13^C NMR spectrum ([Table 1](#marinedrugs-18-00303-t001){ref-type="table"}). It contained a hydroxy, a γ-lactone carbonyl and a double bond due to the IR absorption bands at 3435, 1768 and 1643 cm^−1^, respectively. Interpretations of the ^1^H NMR data along with the HSQC spectrum of compound **5** showed two methyl signals at δ~H~ 3.36 (s, H~3~-10) and 1.24 (t, *J* = 7.1 Hz, H~3~-10), two oxygenated methylene signals at δ~H~ 4.40 (d, *J* = 6.9 Hz, H~2~-6) and 3.63 (m, H~2~-8), two olefinic methine signals at δ~H~ 6.31 (s, H-2) and 5.85 (t, *J* = 6.9 Hz, H-5) and one dioxygenated methine signal at δ~H~ 5.52 (s, H-7) ([Table 2](#marinedrugs-18-00303-t002){ref-type="table"}). The ^13^C NMR data of compound **5** coupled with its phase-sensitive HSQC assignments showed one methoxyl carbon at δ~C~ 53.2 (C-10), one methyl carbon at δ~C~ 15.4 (C-9), two oxygenated methylene carbons at δ~C~ 62.8 (C-8) and 57.3 (C-6), two olefinic methine carbons at δ~C~ 119.7 (C-2) and 115.3 (C-5), one dioxygenated methine carbon at δ~C~ 97.6 (C-7) and three nonprotonated carbons at δ~C~ 169.6 (C-1), 156.5 (C-3) and 148.2 (C-4) ([Table 1](#marinedrugs-18-00303-t001){ref-type="table"}). Correlations of δ~H~ 5.85 (H-5)/δ~H~ 4.40 (H~2~-6) and δ~H~ 3.63 (H~2~-8)/δ~H~ 1.24 (H~3~-9) in the COSY spectrum of compound **5** accompanied with key correlations including δ~H~ 6.31 (H-2)/δ~C~ 169.6 (C-1), 156.5 (C-3), 148.2 (C-4) and 97.6 (C-7); δ~H~ 5.58 (H-5)/δ~C~ 156.5 (C-3) and 148.2 (C-4); δ~H~ 3.63 (H~2~-8)/δ~C~ 97.6 (C-7); δ~H~ 3.36 (H-10)/δ~C~ 97.6 (C-7) in the HMBC spectrum of compound **5** ([Figure 2](#marinedrugs-18-00303-f002){ref-type="fig"}), established the gross structure of **5**. The configuration of Δ^4^ in compound **5** was determined to be *E* form based on a key correlation of δ~H~ 4.40 (H~2~-6)/δ~H~ 5.52 (H-7) in the ROESY of compound **5** ([Figure 2](#marinedrugs-18-00303-f002){ref-type="fig"}). Since compound **5** had an acetal carbon at its C-7 and an optical rotation value close to zero (\[α\] ^27^~D~ +0.02), compound **5** was deduced to be an acetal racemate.

The ^1^H NMR data of compounds **6** and **7** were almost identical with that of compound **3** except that an olefinic proton at δ~H~ 6.02 (H-5) in compound **3** was substituted by a methylene group at δ~H~ 1.91 and 2.38 (H~2~-5) in compound **6** and δ~H~ 1.99 and 2.34 (H~2~-5) in compound **7** and an additional methoxyl functionality at δ~H~ 3.23 (H~3~-9) and δ~H~ 3.19 (H~3~-9) was observed in compound **6** and compound **7** ([Table 2](#marinedrugs-18-00303-t002){ref-type="table"}), respectively. These changes also reflected in their ^13^C NMR data ([Table 1](#marinedrugs-18-00303-t001){ref-type="table"}), in which two olefinic signals at δ~C~ 150.9 (C-4) and 109.3 (C-5) in compound **3** were replaced by a ketal carbon signal (δ~C-4~ 107.6 in **6**; δ~C-4~ 107.2 in **7**) along with a methylene carbon resonance (δ~C-5~ 40.3 in **6**; δ~C-5~ 41.9 in **7**). The additional methoxyl groups in compounds **6** and **7** were deduced to be attached at C-4 due to key cross-peaks of H~3~-9/C-4 in the HMBC spectra of both compound **6** and compound **7** ([Figure 2](#marinedrugs-18-00303-f002){ref-type="fig"}). In the ROESY spectra of compounds **6** and **7**, a key correlation of δ~H~ 3.23 (H~3~-9)/δ~H~ 5.11 (H-7) confirmed that two methoxyls in compound **6** were oriented in different phases, while a key cross-peak of δ~H~ 3.46 (H~3~-8)/δ~H~ 3.19 (H~3~-9) indicated that two methoxyls in compound **7** were located on the same side ([Figure 2](#marinedrugs-18-00303-f002){ref-type="fig"}). The structures of compounds **6** and **7** were thus established as shown in [Figure 1](#marinedrugs-18-00303-f001){ref-type="fig"}.

2.2. Anticancer and Anti-Angiogenic Assays of Secondary Metabolites {#sec2dot2-marinedrugs-18-00303}
-------------------------------------------------------------------

All eleven pure isolates were subjected to biological assays. Among these, compound **3** exerted promising anticancer activities against human hepatocellular carcinoma SK-Hep-1 cells and prostate cancer PC-3 cells with IC~50~ values of 2.7 ± 0.2 and 7.3 ± 0.3 μM ([Table 3](#marinedrugs-18-00303-t003){ref-type="table"}). Paclitaxel, a well-known anticancer agent, was used as the positive control. Additionally, we evaluated the anti-angiogenic activities of all the pure isolates against human endothelial progenitor cells (EPCs). As shown in [Table 3](#marinedrugs-18-00303-t003){ref-type="table"}, compound **3** and patulin exhibited most potent anti-angiogenic activities by suppressing EPCs growth with IC~50~ values of 4.6 ± 0.3 and 4.7 ± 0.2 μM, respectively. Since capillary-like tubules are the essential characteristic of angiogenesis, we next performed tube formation assay to validate the anti-angiogenic effects of compound **3** and patulin in EPCs with sorafenib as a positive control. The results showed that compound **3** and patulin concentration-dependently inhibited capillary tube formation of EPCs ([Figure 3](#marinedrugs-18-00303-f003){ref-type="fig"}A,B). Furthermore, it was found that compound **3** and patulin did not induce the release of lactate dehydrogenase (LDH) in EPCs ([Figure 3](#marinedrugs-18-00303-f003){ref-type="fig"}C), suggesting that these two compounds display anti-angiogenesis property without the cytotoxic fashion. Compound **4** bearing an ethoxyl group at its C-7 instead of a hydroxy and a methoxyl at C-7 of patulin and **3**, respectively, reduced its bioactivity significantly. It was thus speculated that the size of the functional group attached at C-7 and an olefinic functionality at C-4 of patulin could play crucial roles in the anticancer and anti-angiogenic activities. These findings provide evidences that both compound **3** and patulin may serve as the potential natural products to block tumor angiogenesis for cancer treatment.

3. Materials and Methods {#sec3-marinedrugs-18-00303}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-18-00303}
------------------------------------

Optical rotations and UV were measured on a JASCO *P-*2000 polarimeter (Tokyo, Japan) and Thermo UV-Visible Heλios α Spectrophotometer (Bellefonte, CA, USA), respectively. ^1^H and ^13^C NMR were acquired on Bruker AVIII HD 400 and Bruker AVIII-500 spectrometer (Ettlingen, Germany). Low and high resolution mass spectra were obtained using an API4000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA, USA) and Q Exactive Plus Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher Scientific, Bremen, Germany), respectively. IR spectra were recorded on a JASCO FT/IR 4100 spectrometer (Tokyo, Japan). Sephadex LH-20 (GE Healthcare, Uppsala, Sweden) and Diaion HP-20 (Mitsubishi Chemical, Tokyo, Japan) was used for open column chromatography. An HPLC pump L-7100 (Hitachi, Japan) equipped with a refractive index detector (Bischoff, Leonberg, Germany) was used for compound purification. All the organic solvents were purchased from Merck (Darmstadt, Germany).

3.2. Fungal Strain and Culture {#sec3dot2-marinedrugs-18-00303}
------------------------------

*Aspergillus giganteus* NTU967 was isolated from the marine green alga *Ulva lactuca* collected from the northeast coast of Taiwan and was identified by sequencing of the internal transcribed spacer regions of the rDNA (ITS) and β-tubulin gene. A BLAST search of the ITS sequence (GenBank accession no. MH250052) was not conclusive and led to the best matches as *Aspergillus clavatoanicus*, *A. clavatus*, *A. giganteus* and *A. longivesica* (query coverage 94--100%, identity 98--99%) while a BLAST search of the β-tubulin gene resulted the best matches as *A. giganteus* (query coverage 97--100%, identity 98.48--99.63%). For liquid culture, the mycelium of *Aspergillus giganteus* NTU967 was inoculated into 5 L serum bottles, each containing 2 g Peptone (Becton, Dickinson and Company, Sparks, MD, USA), 1 g yeast extract (Becton, Dickinson and Company, Sparks, MD, USA), 10 g Dextrose (Becton, Dickinson and Company, Sparks, MD, USA) and 2.5 L deionized water. The fermentation was conducted with aeration at 25--30 °C for 16 days. For solid culture, the mycelium of *Aspergillus giganteus* NTU967 was inoculated into 500 mL flasks, each containing 50 g brown rice (Santacruz, Taiwan), 2% yeast extract (Becton, Dickinson and Company, Sparks, MD, USA), 1% sodium tartrate and 1% KH~2~HPO~4~ in 20 mL deionized water. The solid culture was conducted at 25--30 °C for 30 days.

3.3. Extraction and Isolation of Secondary Metabolites {#sec3dot3-marinedrugs-18-00303}
------------------------------------------------------

For liquid culture, the filtered fermented broth (15.0 L) of *Aspergillus giganteus* NTU967 was partitioned three times with 30 L EtOAc, then concentrated in vacuum to dryness (8.0 g). Subsequently, the crude extract was redissolved in 20 mL MeOH, then applied onto a Sephadex LH-20 column (2.5 cm i.d. × 68 cm) eluted with MeOH at a flow rate of 2.5 mL/min. Each fraction (20 mL) collected was checked for its compositions by TLC using CH~2~Cl~2~-MeOH (10:1, *v*/*v*) for development, and dipping in vanillin--H~2~SO~4~ was used in the detection of compounds with similar skeletons. All the fractions were combined into four samples I--VI. Subsequently, sample III with antimicrobial activity was precoated with 15.0 g Diaion HP-20 gel, then applied onto a Diaion HP-20 column (4.5 cm i.d. × 30 cm) eluted with mixtures of H~2~O/MeOH in a stepwise gradient mode with a flow rate of 2.0 mL/min to obtain four subsamples I--IV. Subsample III eluted by 75% MeOH was rechromatographed on a semipreparative reversed-phase column (Phenomenex Luna 5 μ PFP, 10 × 250 mm) with 35% MeOH~aq~ as eluent, 2 mL/min, to afford **1** (30.4 mg, *t~R~* = 13.5 min), **2** (15.2 mg, *t~R~* = 16.9 min) and **3** (27.4 mg, *t~R~* = 27.5 min). Subsample III was further purified on a semipreparative reversed-phase column (Thermo Hypersil 5 μ C~18~, 10 × 250 mm) with 25% MeCN~aq~ as eluent, 2 mL/min, to give **4** (22.8 mg, *t~R~* = 35.1 min), **5** (18.4 mg, *t~R~* = 23.4 min), **6** (16.6 mg, *t~R~* = 26.1 min) and **7** (35.6 mg, *t~R~* = 27.6 min).

For solid--state culture, the fermented products were lyophilized, ground into powder (750 g) and extracted three times with equal volumes of methanol. Extracts were first partitioned with *n*-hexane and the methanol layers suspended in deionized H~2~O, then partitioned with ethyl acetate and concentrated to obtain dried ethyl acetate extract (7.0 g). For compound separation, the ethyl acetate extract was subjected to Sephadex LH-20 column chromatography (2.5 i.d. × 68.0 cm), using methanol as the eluent at a flow rate of 2.5 mL/min to give 30 fractions (20.0 mL/fr.). All the fractions were combined into 6 samples as I--VI based on the results of TLC analysis and antimicrobial assay. Sample III with antimicrobial activity was precoated with 20.0 g Diaion HP-20 gel, then applied onto a Diaion HP-20 column (4.5 cm i.d. × 30 cm) eluted with mixtures of H~2~O/MeOH in a stepwise gradient mode with a flow rate of 2.0 mL/min to get four subsamples I--IV. Subsample II eluted by 50% MeOH was rechromatographed on a semipreparative reversed-phase column (BIOSIL Pro-ODS-U 5 μ, 10 × 250 mm) with 15% MeOH~aq~ as eluent, 2 mL/min, to obtain patulin (16.7 mg, *t~R~* = 20.1 min). Subsample IV eluted by 100% MeOH was further purified on a semipreparative reversed-phase column (Phenomenex Luna 5 µ PFP, 10 × 250 mm) with 75% MeOH~aq~ as eluent, 2 mL/min, to afford quinadoline B (27.7 mg, *t~R~* = 11.8 min), deoxytryptoquivaline (21.0 mg, *t~R~* = 23.0 min) and tryptoquivaline (16.4 mg, *t~R~* = 36.2 min).

*Aspergilsmin A* (**1**): Colorless oil; \[α\] ^27^~D~ −0.36 (*c* = 0.05, MeOH); IR (ZnSe) ν~max~: 2951, 1745, 1672, 1611, 1456, 1438, 1399, 1333, 1308, 1283, 1254, 1196, 1171, 1105, 1055, 1033 and 1009 cm^−1^; UV λ~max~ (MeOH) (log ε) 261 (3.9) nm; ^1^H and ^13^C NMR spectroscopic data: see [Table 1](#marinedrugs-18-00303-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00303-t002){ref-type="table"}; HRESIMS \[M + Na\]^+^ at *m*/*z* 223.0574 (calcd. 223.0582 for C~9~H~12~O~5~Na).

*Aspergilsmin B* (**2**): Colorless oil; \[α\] ^27^~D~ +1.22 (*c* = 0.05, MeOH); IR (ZnSe) ν~max~: 2947, 1737, 1673, 1619, 1443, 1406, 1344, 1291, 1257, 1157, 1097, 1056, 1043, 1024, 1011 and 854 cm^−1^; UV λ~max~ (MeOH) (log ε) 268 (3.9) nm; ^1^H and ^13^C NMR spectroscopic data: see [Table 1](#marinedrugs-18-00303-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00303-t002){ref-type="table"}; HRESIMS \[M + Na\]^+^ at *m*/*z* 223.0573 (calcd. 223.0582 for C~9~H~12~O~5~Na).

*Aspergilsmin C* (**3**): Colorless oil; \[α\] ^27^~D~ −3.52 (*c* = 0.05, MeOH); IR (ZnSe) ν~max~: 2955, 1780, 1536, 1443, 1406, 1344, 1210, 1065 and 868 cm^−1^; UV λ~max~ (MeOH) (log ε) 274 (4.0) nm; ^1^H and ^13^C NMR spectroscopic data: see [Table 1](#marinedrugs-18-00303-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00303-t002){ref-type="table"}; HRESIMS \[M + H\]^+^ at *m*/*z* 169.0493 (calcd. 169.0501 for C~8~H~9~O~4~).

*Aspergilsmin D* (**4**): Colorless oil; \[α\] ^27^~D~ −2.14 (*c* = 0.05, MeOH); IR (ZnSe) ν~max~: 2945, 1780, 1635, 1404, 1092 and 1019 cm^−1^; UV λ~max~ (MeOH) (log ε) 275 (4.0) nm; ^1^H and ^13^C NMR spectroscopic data: see [Table 1](#marinedrugs-18-00303-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00303-t002){ref-type="table"}; HRESIMS \[M + H\]^+^ at *m*/*z* 183.0655 (calcd. 183.0657 for C~9~H~11~O~4~).

*Aspergilsmin E* (**5**): Colorless oil; \[α\] ^27^~D~ +0.02 (*c* = 0.05, MeOH); IR (ZnSe) ν~max~: 3435, 1768, 1643, 1053 and 1008 cm^−1^; UV λ~max~ (MeOH) (log ε) 223 (3.7) and 270 (4.0) nm; ^1^H and ^13^C NMR spectroscopic data: see [Table 1](#marinedrugs-18-00303-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00303-t002){ref-type="table"}; HRESIMS \[M + H\]^+^ at *m*/*z* 215.0915 (calcd. 215.0947 for C~10~H~15~O~5~).

*Aspergilsmin F* (**6**): Colorless oil; \[α\] ^27^~D~ −0.53 (*c* = 0.05, MeOH); IR (ZnSe) ν~max~: 2951, 1768, 1643, 1456, 1396, 1207, 1163, 1082, 1022 and 972 cm^−1^; UV λ~max~ (MeOH) (log ε) 257 (4.1) nm; ^1^H and ^13^C NMR spectroscopic data: see [Table 1](#marinedrugs-18-00303-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00303-t002){ref-type="table"}; HRESIMS \[M + Na\]^+^ at *m*/*z* 223.0579 (calcd. 223.0582 for C~9~H~12~O~5~Na).

*Aspergilsmin G* (**7**): Colorless oil; \[α\] ^27^~D~ −1.86 (*c* = 0.05, MeOH); IR (ZnSe) ν~max~: 2971, 2842, 1766, 1456, 1435, 1358, 1329, 1266, 1205, 1196, 1171, 1129, 1041, 1034 and 915 cm^−1^; UV λ~max~ (MeOH) (log ε) 271 (4.0) nm; ^1^H and ^13^C NMR spectroscopic data: see [Table 1](#marinedrugs-18-00303-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00303-t002){ref-type="table"}; HRESIMS \[M + Na\]^+^ at *m*/*z* 223.0574 (calcd. 223.0582 for C~9~H~12~O~5~Na).

3.4. Cell Culture {#sec3dot4-marinedrugs-18-00303}
-----------------

The human hepatocellular carcinoma cell line SK-Hep-1 and hormone refractory prostate cancer cell line PC-3 were purchased from the American Type Cell Culture Collection (Manassas, VA, USA) and maintained in DMEM medium containing 10% fetal bovine serum (FBS), penicillin (100 units/mL) and streptomycin (100 μg/mL). Cells were maintained in humidified air containing 5% CO~2~ at 37 °C. All cell culture reagents were purchased from Gibco-BRL life technologies (Grand Island, NY, USA). The isolation and maintenance of human CD34-positive endothelial progenitor cells (EPCs) were conducted using the standard method as previously described \[[@B15-marinedrugs-18-00303]\].

3.5. Biologic Assay for Anticancer Activity {#sec3dot5-marinedrugs-18-00303}
-------------------------------------------

SK-Hep-1 and PC-3 cancer cells were seeded onto 96-well plates in a density of 5 × 10^3^ cells per well. Overnight, cells were treated with the tested compounds for 48 h. Then, anticancer activity was determined by the SRB assay according to previously described procedures \[[@B16-marinedrugs-18-00303]\].

3.6. Biologic Assay for Anti-Angiogenic Activity {#sec3dot6-marinedrugs-18-00303}
------------------------------------------------

For EPCs' cell growth assay, EPCs were cultured in 96-well plates at a density of 5 × 10^3^ cells in each well. Overnight, the culture medium was replaced with MV2 complete medium containing 2% FBS in the presence of the tested compounds for 48 h. The reaction was terminated after 48 h of incubation with 50% TCA. After the TCA fixation, every well was incubated for 15 min incubation with 0.4% sulforhodamine B in 1% acetic acid. The plates were then washed before the dye was dissolved by 10-mM Tris buffer. Absorbance density values were read by an enzyme-linked immunosorbent assay (ELISA) reader (515 nm).

For EPCs' tube formation assay, EPCs were seeded with the density of 1.25 × 10^4^ cells per well in Matrigel-coated 96-well plates and incubated in an MV2 complete medium containing 2% FBS and the tested compounds for 24 h. EPCs differentiation and capillary-like tube formation was taken with the inverted phase contrast microscope. The long axis of each tube was measured with MacBiophotonics Image J software in 3 randomly chosen fields per well.

For EPCs' cytotoxicity assay, EPCs (5 × 10^3^ cells/well) were seeded onto 96-well plates and incubated with MV2 complete medium containing 2% FBS and the tested compounds for 24 h. Then, the quantification of LDH release in the medium was done with a cytotoxicity assay kit.

4. Conclusions {#sec4-marinedrugs-18-00303}
==============

In this report, we have identified seven new polyketides **1**--**7** along with four known compounds from a marine algicolous fungal strain *Aspergillus giganteus* NTU967. Of the compounds identified, compound **3** and its known analog patulin exhibited promising anticancer as well as significant anti-angiogenic activities when compared with the clinically used drugs.

We thank S.-L.H. and S.-Y.S. in the Instrumentation Center of the College of Science, National Taiwan University for the NMR and MS data acquisition, respectively.

The following are available online at <https://www.mdpi.com/1660-3397/18/6/303/s1>, Figures S1--S38: All the NMR spectra of compounds **1**--**7**. Figure S39: The structures of known compounds isolated in this study. Table S1: Cytotoxicities of aspergilsmins A-G (**1**--**7**), patulin, deoxytryptoquivaline, tryptoquivaline and quinadoline B against PC-3 and SK-Hep-1 cells.
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Click here for additional data file.
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![Chemical structures of compounds **1**--**7** and patulin.](marinedrugs-18-00303-g001){#marinedrugs-18-00303-f001}

![COSY and key HMBC and ROESY correlations of compounds **1**, **2**, **5**, **6** and **7**.](marinedrugs-18-00303-g002){#marinedrugs-18-00303-f002}

![Effects of compound **3** and patulin on tube formation and cytotoxicity of human EPCs. (**A**) EPCs were treated with compound **3**, patulin and sorafenib (10 μM) for 24 h. Tubular morphogenesis was recorded by the inverted phase contrast microscope. Representative images of EPCs' tube formation were shown; (**B**) tube formation was quantified by measuring the length of tubes using ImageJ software; (**C**) Cells were treated with the indicated compounds for 24 h, then the cytotoxicity was determined using LDH assay Data represent the mean ± S.E.M. of 4 independent experiments. \* *p* \< 0.05 compared with the control group.](marinedrugs-18-00303-g003){#marinedrugs-18-00303-f003}

marinedrugs-18-00303-t001_Table 1

###### 

^13^C NMR spectroscopic data for compounds **1**--**7** (δ in ppm, mult.).

  No.   1 *^a,b^*   2 *^a,b^*   3 *^a,b^*   4 *^a,b^*   5 *^a,b^*   6 *^a,b^*   7 *^a,b^*
  ----- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  1     172.9 s     173.6 s     170.6 s     170.6 s     169.6 s     170.6 s     170.6 s
  2     36.7 t      31.1 t      111.9 d     111.1 d     119.7 d     117.1 d     119.9 d
  3     69.7 d      111.7 s     147.5 s     147.6 s     156.5 s     163.9 s     160.9 s
  4     191.8 s     191.3 s     150.9 s     151.3 s     148.2 s     107.6 s     107.2 s
  5     116.2 s     77.3 d      109.3 d     109.4 d     115.3 d     40.3 t      41.9 t
  6     166.1 d     72.3 t      60.0 t      60.0 t      57.3 t      62.3 t      58.3 t
  7     75.9 t      164.0 d     95.9 d      94.8 d      97.6 d      98.8 d      97.4 d
  8     57.7 q      58.7 q      56.5 q      65.6 t      62.8 t      57.3 q      55.5 q
  9     52.7 q      52.5 q                  15.4 q      15.4 q      51.2 q      52.2 q
  10                                                    53.2 q                  

***^a^*** Measured in CD~3~OD (125 MHz); ***^b^*** Multiplicties were obtained from phase-sensitive HSQC experiments.

marinedrugs-18-00303-t002_Table 2

###### 

^1^H NMR spectroscopic data for compounds **1**--**7** (δ in ppm, mult., *J* in Hz).

  No.   1 *^a^*        2 *^b^*        3 *^b^*               4 *^b^*               5 *^b^*        6 *^b^*               7 *^b^*
  ----- -------------- -------------- --------------------- --------------------- -------------- --------------------- ---------------------
  1                                                                                                                    
  2     2.61 d (6.2)   3.14 s         6.60 s                6.05 s                6.31 s         6.12 s                6.23 s
  3     4.55 *^c^*                                                                                                     
  4                                                                                                                    
  5                    3.70 t (4.7)   6.02 m                6.02 m                5.85 t (6.9)   1.91 m                1.99 m
                                                                                                 2.38 dt (13.5, 2.1)   2.34 d (13.2)
  6     7.66 s         4.49 d (4.7)   4.37 dd (17.5, 4.4)   4.36 dd (17.3, 4.4)   4.40 d (6.9)   3.76 td (12.2, 2.1)   3.71 m
                                      4.56 dd (17.5, 2.5)   4.56 dd (17.3, 2.6)                  4.01 m                4.10 td (12.0, 2.0)
  7     4.55 *^c^*     7.50 s         5.68 s                5.79 s                5.52 s         5.11 s                5.52 s
  8     3.35 s         3.45 s         3.54 s                3.71 m                3.63 m         3.60 s                3.46 s
                                                            3.91 m                                                     
  9     3.71 s         3.67 s                               1.26 t (7.1)          1.24 t (7.1)   3.23 s                3.19 s
  10                                                                              3.36 s                               

*^a^* Measured in CD~3~OD (400 MHz); *^b^* Measured in CD~3~OD (500 MHz); ^c^ Signals were overlapped and were picked up from HSQC spectrum.
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###### 

Anticancer and anti-angiogenic activities of compound **3** and patulin.

  Compounds              Anticancer (IC~50~, μM)   Anti-Angiogenesis (IC~50~, μM)   
  ---------------------- ------------------------- -------------------------------- -----------
  Compound **3**         2.7 ± 0.2                 7.3 ± 0.3                        4.6 ± 0.3
  Patulin                2.9 ± 0.1                 2.7 ± 0.1                        4.7 ± 0.2
  Paclitaxel ***^d^***   0.011 ± 0.002             0.013 ± 0.002                    --
  Sorafenib ***^d^***    --                        --                               4.8 ± 0.3

***^a^*** Hepatocellular carcinoma cells; ***^b^*** Prostate cancer cells; ***^c^*** Endothelial progenitor cells; ***^d^*** Positive control.

[^1]: These authors contributed equally to this work.
